FDA 483 - Corden Pharma S.p.A. - July 15, 2016
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
During an inspection from July 7-15, 2016, the FDA observed significant deficiencies at Corden Pharma S.p.A. in Caponago, Italy, a drug manufacturer. The findings primarily concern inadequate laboratory controls, including unvalidated test methods and incomplete records, as well as issues with facility maintenance, personnel gowning, and quality system investigations into product complaints. These observations indicate a lack of adherence to good manufacturing practices.
ID · 30a951db-d279-4ffd-8b14-95a83d8dbe1b